Discovery of indeno[1,2- c ]quinoline derivatives as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand (RANKL)

Journal of Medicinal Chemistry

Volumn 54, Issue 8, 2011, Pages 3103-3107

  Tseng, Chih Hua ^a   Lin, Ru Wei ^b   Chen, Yeh Long ^a   Wang, Gwo Jaw ^b,c   Ho, Mei Ling ^b,d   Tzeng, Cherng Chyi ^a  

^a Department of Medicinal and Applied Chemistry   (Taiwan)

^b Orthopaedic Research Center   (Taiwan)

^c Institute of Clinical Medicine and Cardiovascular Research Institute   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

6,9 DIMETHOXY 11H INDENO[1,2 C]QUINOLIN 11 ONE; 9 METHOXY 6 (METHYLTHIO) 11H INDENO[1,2 C]QUINOLIN 11 ONE; GENISTEIN; INDENO[1,2 C]QUINOLINE DERIVATIVE; IPRIFLAVONE; OSTEOCLAST DIFFERENTIATION FACTOR; QUINOLINE DERIVATIVE; RALOXIFENE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; NONHUMAN; OSTEOCLASTOGENESIS;

DRUG DISCOVERY; HUMANS; INDENES; OSTEOCLASTS; QUINOLINES; RANK LIGAND;

EID: 79955366218     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1016494     Document Type: Article

References (21)

1. Rodan, G. A.; Martin, T. J. Therapeutic approaches to bone diseases Science 2000, 289, 1508-1514
2. Sato, M.; Grese, T. A.; Dodge, J. A.; Bryant, H. U.; Turner, C. H. Emerging therapies for the prevention or treatment of postmenopausal osteoporosis J. Med. Chem. 1999, 42, 1-24 (Pubitemid 29056485)
3. Kauffman, R. F.; Bryant, H. U.; Yang, N.; Harper, K. D.; Huster, W. J.; Walls, E. L. Preventing post-menopausal osteoporosis: an update on raloxifene Drug News Perspect. 1999, 12, 223-233 (Pubitemid 29300067)
4. Colditz, G. A.; Hankinson, S. E.; Hunter, D. J.; Willett, W. C.; Manson, J. E.; Stampfer, M. J.; Hennekens, C.; Rosner, B.; Speizer, F. E. The use of estrogens and progestin and the risk of breast cancer in post-menopausal women N. Engl. J. Med. 1995, 332, 1589-1593
5. Beresford, S. A.; Weiss, N. S.; Voigt, L. F.; McKnight, B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women Lancet 1997, 349, 458-461 (Pubitemid 27077825)
6. Sun, W.; Cama, L. D.; Birzin, E. T.; Warrier, S.; Locco, L.; Mosley, R.; Hammond, M. L.; Rohrer, S. P. 6 H -Benzo[ c ]chromen-6-one derivatives as selective ERbeta agonists Bioorg. Med. Chem. Lett. 2006, 16, 1468-1472 (Pubitemid 43197502)
7. O'Neill, K.; Chen, S.; Brinton, R. D. Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease Exp. Neurol. 2004, 185, 63-80 (Pubitemid 38010279)
8. Yamaguchi, M.; Gao, Y. H. Inhibitory effect of genistein on bone resorption in tissue culture Biochem. Pharmacol. 1998, 55, 71-76 (Pubitemid 28101987)
9. Delcanale, M.; Amari, G.; Armani, E.; Lipreri, M.; Civelli, M.; Galbiati, E.; Giossi, M.; Caruso, P. L.; Crivori, P.; Carrupt, P.-A.; Testa, B. Novel basic isoflavones as inhibitors of bone resorption Helv. Chim. Acta 2001, 84, 2417-2429 (Pubitemid 32952450)
10. Wang, S. F.; Jiang, Q.; Ye, Y. H.; Li, Y.; Tan, R. X. Genistein derivatives as selective estrogen receptor modulators: sonochemical synthesis and in vivo anti-osteoporotic action Bioorg. Med. Chem. 2005, 13, 4880-4890 (Pubitemid 40943512)
11. Shino, A.; Tsukuda, R.; Odaka, H.; Kitazaki, T.; Tsuda, M.; Matsuo, T. Suppressive effect of ipriflavone on bone depletion in the experimental diabetic rat: dose response of ipriflavone Life Sci. 1988, 42, 1123-30 (Pubitemid 18069368)
12. Agnusdei, D.; Zacchei, F.; Bigazzi, S.; Cepollaro, C.; Nardi, P.; Montagnani, M.; Gennari, C. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis Drugs Exp. Clin. Res. 1989, 15, 97-104 (Pubitemid 19143430)
13. Reginster, J. Y. Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis Bone Miner. 1993, 23, 223-232
14. Tseng, C. H.; Chen, Y. L.; Lu, C. M.; Wang, C. K.; Tsai, Y. T.; Lin, R. W.; Chen, C. F.; Chang, Y. F.; Wang, G. J.; Ho, M. L.; Tzeng, C. C. Synthesis and anti-osteoporotic evaluation of certain 3-amino-2-hydroxypropoxyisoflavone derivatives Eur. J. Med. Chem. 2009, 44, 3621-3626
15. Zhu, M.; Kim, M. H.; Lee, S.; Bae, S. J.; Kim, S. H.; Park, S. B. Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand J. Med. Chem. 2010, 8760-8764
16. Kamijo, T.; Ujiie, A.; Harada, H.; Tsutsumi, N.; Tsubaki, A.; Yamaguchi, T.; Nagata, H. Acylated Benzofuro[3,2- c ]quinoline Compounds with Utility as Treatments for Osteoporosis. U.S. Patent 5,023,261, 1991.
17. Tseng, C. H.; Chen, Y. L.; Lu, P. J.; Yang, C. N.; Tzeng, C. C. Synthesis and antiproliferative evaluation of certain indeno[1,2- c ]quinoline derivatives Bioorg. Med. Chem. 2008, 15, 3153-3162
18. Tseng, C. H.; Chen, Y. L.; Chung, K. Y.; Cheng, C. M.; Wang, C. H.; Tzeng, C. C. Synthesis and antiproliferative evaluation of 6-arylindeno[1,2- c ]quinoline derivatives Bioorg. Med. Chem. 2009, 17, 7465-7476
19. Tseng, C. H.; Tzeng, C. C.; Yang, C. L.; Lu, P. J.; Chen, H. L.; Li., H. Y.; Chuang, Y. C.; Yang, C. N.; Chen, Y. L. Synthesis and antiproliferative evaluation of certain indeno[1,2- c ]quinoline derivatives. Part 2 J. Med. Chem. 2010, 53, 6164-6179
20. Boyle, W. J.; Simonet, W. S.; Lacey, D. L. Osteoclast differentiation and activation Nature 2003, 423, 337-342 (Pubitemid 40852708)
21. Lee, J. H.; Jin, H.; Shim, H. E.; Kim, H. N.; Na, H.; Lee, Z. H. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-κB signal Mol. Pharmacol. 2010, 77, 17-25